Cardiovascular Drugs Practice Questions

Q: Which medication is most commonly associated with drug-induced peripheral edema?

Amlodipine. ***Amlodipine*** - **Dihydropyridine calcium channel blockers** like amlodipine are notorious for causing drug-induced peripheral edema. - This is due to **preferential precapillary vasodilation**, leading to increased hydrostatic pressure in capillaries. *Furosemide* - **Furosemide** is a loop diuretic, which is used to *treat* edema by promoting diuresis and reducing fluid retention. - It works by inhibiting the reabsorption of sodium and chloride in the **ascending loop of Henle**. *Hydrochlorothiazide* - **Hydrochlorothiazide** is a thiazide diuretic, also used to *treat* edema and hypertension. - It primarily acts on the **distal convoluted tubule** to inhibit sodium and chloride reabsorption. *Atenolol* - **Atenolol** is a beta-blocker primarily used for hypertension and angina. - While beta-blockers can cause various side effects, **peripheral edema** is not a common or direct side effect of atenolol.

Q: A 55-year-old patient with hypertension and diabetes is prescribed an ACE inhibitor. What is the PRIMARY reason ACE inhibitors are preferred over beta-blockers in this scenario?

Renal protection from diabetic nephropathy. ***Renal protection from diabetic nephropathy*** - ACE inhibitors significantly **slow the progression of diabetic nephropathy** by reducing intraglomerular pressure and proteinuria, which is crucial in patients with both hypertension and diabetes. - They are considered **first-line agents** for hypertension in diabetic patients due to their established renoprotective benefits, even independent of their blood pressure-lowering effects. *Lower risk of hypoglycemia with ACE inhibitors* - While beta-blockers *can* mask hypoglycemia symptoms and impair glucose recovery, avoiding hypoglycemia is not the primary reason ACE inhibitors are preferred generally in this scenario. - The direct **cardiovascular and renal protective benefits** of ACE inhibitors are the main differentiating factor. *Reduced cardiac output is a concern* - Beta-blockers, by their mechanism of action, can reduce cardiac output, which might be a concern in certain patients with pre-existing heart conditions but it is not the primary reason for preferring ACE inhibitors in *this* general scenario. - ACE inhibitors generally have a more favorable profile for long-term **cardiovascular remodeling** and **heart failure prevention** in diabetic patients. *No significant effect on glucose metabolism* - While ACE inhibitors are generally **metabolically neutral** and do not adversely affect glucose metabolism, this is a secondary benefit. - Beta-blockers, particularly non-selective ones, can negatively impact glucose metabolism by impairing insulin sensitivity and masking hypoglycemic symptoms.

Q: A patient with hyperlipidemia is prescribed a medication that inhibits the enzyme HMG-CoA reductase. To which drug class does this medication belong?

Statins. ***Statins*** - **Statins** are the class of drugs that specifically work by **inhibiting HMG-CoA reductase**, which is the rate-limiting enzyme in cholesterol synthesis in the liver. - This inhibition leads to decreased cholesterol production, increased LDL receptor expression, and thus lower **LDL-cholesterol** levels. *Fibrates* - **Fibrates** primarily activate **peroxisome proliferator-activated receptor alpha (PPAR-α)**, which alters lipid metabolism. - Their main effect is to **reduce triglyceride levels** and increase HDL-cholesterol, not directly inhibit HMG-CoA reductase. *Bile acid sequestrants* - **Bile acid sequestrants** are resins that bind **bile acids** in the intestine, preventing their reabsorption. - This increases the excretion of bile acids, prompting the liver to convert more cholesterol into bile acids, thereby lowering **LDL-cholesterol** levels indirectly. *Niacin derivatives* - **Niacin** (vitamin B3) works by inhibiting fatty acid release from adipose tissue and reducing hepatic synthesis of VLDL and LDL. - Its primary mechanism involves activating a specific receptor (GPR109A) in adipocytes, leading to a decrease in **triglyceride** and **LDL-cholesterol** and an increase in HDL-cholesterol.

Q: In a clinical trial examining the effects of a new antihypertensive drug, which primary endpoint would most accurately measure the drug's efficacy?

Decrease in diastolic blood pressure. ***Decrease in diastolic blood pressure*** - The primary goal of an **antihypertensive drug** is to lower blood pressure. A significant decrease in **diastolic blood pressure** directly indicates the drug's efficacy in achieving this goal. - Diastolic blood pressure is a crucial measure of the **pressure in the arteries** when the heart rests between beats, reflecting the overall vascular resistance and a key indicator for hypertension management. *Increase in diastolic blood pressure* - An **increase in diastolic blood pressure** would indicate the drug is ineffective or even harmful, as it exacerbates the condition it is meant to treat. - This outcome would be contrary to the purpose of an **antihypertensive medication**, which aims to lower elevated blood pressure. *Change in heart rate variability* - While changes in **heart rate variability (HRV)** can reflect autonomic nervous system activity and might be influenced by antihypertensive drugs, it is not a direct or primary measure of blood pressure reduction. - HRV is a secondary endpoint that may provide insights into cardiovascular health but does not directly quantify the drug's effectiveness in lowering blood pressure. *Change in blood viscosity* - **Blood viscosity** relates to the thickness and stickiness of blood, which can impact blood flow and pressure. However, it is not a direct or primary endpoint for evaluating the efficacy of most standard antihypertensive drugs. - While some drugs might indirectly affect viscosity, the direct and most relevant measure for hypertension treatment efficacy is the reduction in **blood pressure values**.

Q: A patient with chronic atrial fibrillation is on digoxin. What is the primary mechanism of action of digoxin?

Inhibition of Na+/K+ ATPase. ***Inhibition of Na+/K+ ATPase*** - Digoxin directly inhibits the **Na+/K+ ATPase pump** in cardiac myocytes, leading to increased intracellular sodium [1]. - This increased sodium then reduces the activity of the **Na+/Ca2+ exchanger**, resulting in increased intracellular calcium and enhanced myocardial contractility [3]. *Beta-blockade* - Beta-blockers primarily reduce heart rate and contractility by blocking the effects of **norepinephrine** and **epinephrine** at beta-adrenergic receptors [2]. - Digoxin does not exert its primary therapeutic effects through this mechanism. *Calcium channel blockade* - Calcium channel blockers typically reduce the influx of **calcium ions** into cardiac and smooth muscle cells, leading to decreased contractility and vasodilation. - Digoxin, conversely, increases intracellular calcium to enhance contractility [3]. *Alpha-adrenergic blockade* - Alpha-adrenergic blockers primarily cause **vasodilation** by blocking alpha-receptors, leading to reduced blood pressure. - This mechanism is not relevant to digoxin's therapeutic actions on cardiac rhythm or contractility.

Q: A patient with pulmonary arterial hypertension is prescribed a phosphodiesterase-5 inhibitor to improve exercise capacity and reduce symptoms. Which of the following drugs is most likely to be prescribed?

Sildenafil. **Sildenafil** - **Sildenafil** is a **phosphodiesterase-5 (PDE5) inhibitor** commonly used to treat pulmonary arterial hypertension (PAH) by promoting vasodilation in the pulmonary arteries. - It works by increasing levels of **cyclic guanosine monophosphate (cGMP)**, leading to relaxation of pulmonary vascular smooth muscle, improving exercise capacity, and reducing symptoms. *Bosentan* - **Bosentan** is an **endothelin receptor antagonist**, not a PDE5 inhibitor, and primarily acts by blocking the effects of endothelin-1, a potent vasoconstrictor. - While used in PAH, its mechanism of action is distinct from the requested drug class. *Epoprostenol* - **Epoprostenol** is a synthetic **prostacyclin analogue** that functions as a potent vasodilator and inhibitor of platelet aggregation. - It is administered intravenously and is used in severe PAH, but it is not a PDE5 inhibitor. *Iloprost* - **Iloprost** is also a **prostacyclin analogue**, similar to epoprostenol, and causes vasodilation and anti-platelet effects. - It is typically administered via inhalation but does not belong to the PDE5 inhibitor class.

Q: In a clinical trial for a new antihypertensive drug, researchers measure the drug's effect on reducing diastolic blood pressure. What type of study is this an example of?

Randomized controlled trial. ***Randomized controlled trial*** - This is the **gold standard** for evaluating the efficacy of new interventions. It involves random allocation of participants to either a treatment group (receiving the new drug) or a control group (receiving a placebo or standard treatment). - The comparison of diastolic blood pressure reduction between randomized groups allows for strong causal inferences about the drug's effect, minimizing **bias** and **confounding factors**. *Cohort study* - A **cohort study** observes a group of individuals over time to see who develops an outcome. This type of study would typically track subjects to see if they develop hypertension or other conditions, not to test a new drug's direct effect. - It describes the incidence or natural history of a condition, but does not involve **experimentation** or **intervention**. *Case-control study* - A **case-control study** compares individuals with a disease (**cases**) to individuals without the disease (**controls**) to identify past exposures that may have contributed to the disease. - This design is **retrospective** and is used for understanding disease etiology, not for testing the efficacy of a new drug. *Cross-sectional study* - A **cross-sectional study** measures the prevalence of a disease or health outcome and related factors at a single point in time. - It provides a snapshot of the population's health status and associations but cannot establish **causality** or evaluate the effect of an intervention.

Q: Identify the primary drug used for pharmacological stress testing in echocardiography.

Dobutamine. ***Dobutamine*** - **Dobutamine** is a synthetic catecholamine that stimulates beta-1 adrenergic receptors, increasing **myocardial contractility** and **heart rate**, thereby mimicking the effects of exercise. - It is the most commonly used pharmacological agent for **stress echocardiography** to evaluate for inducible **myocardial ischemia**. *Adenosine* - **Adenosine** is primarily used for **pharmacological stress testing** in **myocardial perfusion imaging (MPI)**, not typically for echocardiography. - It causes **coronary vasodilation**, leading to increased blood flow in healthy vessels, while stenotic vessels cannot dilate, highlighting relative perfusion differences. *Atropine* - **Atropine** is an **anticholinergic drug** used to increase heart rate when the target heart rate is not achieved with dobutamine alone during stress echocardiography. - It is an **adjunct** or **secondary agent**, not the primary drug, for inducing stress. *Diltiazem* - **Diltiazem** is a **calcium channel blocker** used to treat **hypertension** and **angina**, typically decreasing heart rate and myocardial oxygen demand. - It is an **anti-ischemic drug** and would counteract the purpose of a **stress test**, which is to induce and unmask ischemia.

Q: A heart failure patient is treated with an ACE inhibitor. How does this medication influence renal sodium excretion?

Decreases angiotensin II, leading to Na+ excretion. ***Decreases angiotensin II, leading to Na+ excretion*** - ACE inhibitors block the conversion of angiotensin I to **angiotensin II**. Angiotensin II normally promotes sodium reabsorption in the renal tubules and stimulates **aldosterone** release. - By reducing angiotensin II levels, ACE inhibitors lead to **decreased sodium reabsorption** and increased sodium excretion, which helps reduce fluid volume in heart failure. *Decreases angiotensin II, leading to Na+ retention* - While ACE inhibitors do decrease angiotensin II, this effect **reduces sodium reabsorption**, leading to excretion, not retention. - **Sodium retention** would worsen heart failure symptoms due to increased fluid volume. *Increases aldosterone, leading to Na+ retention* - ACE inhibitors actually **decrease aldosterone** secretion, as angiotensin II is a primary stimulus for aldosterone release. - Reduced aldosterone leads to **decreased sodium reabsorption** and potassium excretion. *Increases angiotensin II, leading to Na+ excretion* - ACE inhibitors work by **decreasing**, not increasing, **angiotensin II levels**. - While increased Na+ excretion is the correct outcome, the premise of increased angiotensin II is **incorrect** regarding the mechanism of ACE inhibitors.

Q: What is the primary direct effect of a beta-blocker on cardiac function?

Decrease heart rate. ***Decrease heart rate*** - Beta-blockers primarily antagonize **beta-1 adrenergic receptors** in the heart, leading to reduced sympathetic stimulation. - This antagonism results in **slowing of the sinoatrial (SA) node firing rate**, which directly decreases the heart rate (negative chronotropy). - This is the **most direct and primary pharmacological effect** on cardiac function. *Increase contractility* - Beta-blockers **reduce cardiac contractility** (negative inotropy), not increase it, by blocking beta-1 receptors which are responsible for increasing intracellular calcium and enhancing contraction. - An increase in contractility would be an effect of **beta-agonists** (e.g., dobutamine) or other positive inotropic agents. *Increase heart rate* - Beta-blockers are designed to **decrease heart rate**, not increase it, by blocking the effects of norepinephrine and epinephrine on beta-1 receptors in the SA node. - An increased heart rate is typically seen with **sympathetic activation** or administration of chronotropic agents like atropine. *Decrease myocardial oxygen demand* - While beta-blockers do decrease myocardial oxygen demand, this is a **secondary therapeutic benefit** resulting from their primary actions of reducing heart rate, contractility, and blood pressure. - This is clinically important (especially in angina and MI), but the **primary direct pharmacological effect** is the decrease in heart rate through SA node inhibition.

Question 1

Which medication is most commonly associated with drug-induced peripheral edema?

Accepted Answer

Amlodipine

Answer

Furosemide

Answer

Hydrochlorothiazide

Answer

Atenolol

Question 2

A 55-year-old patient with hypertension and diabetes is prescribed an ACE inhibitor. What is the PRIMARY reason ACE inhibitors are preferred over beta-blockers in this scenario?

Accepted Answer

Renal protection from diabetic nephropathy

Answer

Lower risk of hypoglycemia with ACE inhibitors

Answer

Beta-blockers reduce cardiac output

Answer

No significant effect on glucose metabolism

Question 3

A patient with hyperlipidemia is prescribed a medication that inhibits the enzyme HMG-CoA reductase. To which drug class does this medication belong?

Accepted Answer

Statins

Answer

Fibrates

Answer

Bile acid sequestrants

Answer

Niacin derivatives

Question 4

In a clinical trial examining the effects of a new antihypertensive drug, which primary endpoint would most accurately measure the drug's efficacy?

Accepted Answer

Decrease in diastolic blood pressure

Answer

Increase in diastolic blood pressure

Answer

Change in heart rate variability

Answer

Change in blood viscosity

Question 5

A patient with chronic atrial fibrillation is on digoxin. What is the primary mechanism of action of digoxin?

Accepted Answer

Inhibition of Na+/K+ ATPase

Answer

Beta-blockade

Answer

Calcium channel blockade

Answer

Alpha-adrenergic blockade

Question 6

A patient with pulmonary arterial hypertension is prescribed a phosphodiesterase-5 inhibitor to improve exercise capacity and reduce symptoms. Which of the following drugs is most likely to be prescribed?

Accepted Answer

Sildenafil

Answer

Bosentan

Answer

Epoprostenol

Answer

Iloprost

Question 7

In a clinical trial for a new antihypertensive drug, researchers measure the drug's effect on reducing diastolic blood pressure. What type of study is this an example of?

Accepted Answer

Randomized controlled trial

Answer

Cohort study

Answer

Case-control study

Answer

Cross-sectional study

Question 8

Identify the primary drug used for pharmacological stress testing in echocardiography.

Accepted Answer

Dobutamine

Answer

Adenosine

Answer

Atropine

Answer

Diltiazem

Question 9

A heart failure patient is treated with an ACE inhibitor. How does this medication influence renal sodium excretion?

Accepted Answer

Decreases angiotensin II, leading to Na+ excretion

Answer

Decreases angiotensin II, leading to Na+ retention

Answer

Increases aldosterone, leading to Na+ retention

Answer

Increases angiotensin II, leading to Na+ excretion

Question 10

What is the primary direct effect of a beta-blocker on cardiac function?

Accepted Answer

Decrease heart rate

Answer

Increase contractility

Answer

Increase heart rate

Answer

Decrease myocardial oxygen demand

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?